JP2019201643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019201643A5 JP2019201643A5 JP2019111990A JP2019111990A JP2019201643A5 JP 2019201643 A5 JP2019201643 A5 JP 2019201643A5 JP 2019111990 A JP2019111990 A JP 2019111990A JP 2019111990 A JP2019111990 A JP 2019111990A JP 2019201643 A5 JP2019201643 A5 JP 2019201643A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated antibody
- functional fragment
- antibody
- domain
- collection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 239000013598 vector Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021169020A JP2022028659A (ja) | 2013-06-26 | 2021-10-14 | 新規抗体フレームワーク |
| JP2023199881A JP2024026176A (ja) | 2013-06-26 | 2023-11-27 | 新規抗体フレームワーク |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003264.2 | 2013-06-26 | ||
| EP13003264 | 2013-06-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522319A Division JP6708544B2 (ja) | 2013-06-26 | 2014-06-26 | 新規抗体フレームワーク |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021169020A Division JP2022028659A (ja) | 2013-06-26 | 2021-10-14 | 新規抗体フレームワーク |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019201643A JP2019201643A (ja) | 2019-11-28 |
| JP2019201643A5 true JP2019201643A5 (cg-RX-API-DMAC7.html) | 2020-01-16 |
Family
ID=48699516
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522319A Active JP6708544B2 (ja) | 2013-06-26 | 2014-06-26 | 新規抗体フレームワーク |
| JP2019111990A Withdrawn JP2019201643A (ja) | 2013-06-26 | 2019-06-17 | 新規抗体フレームワーク |
| JP2021169020A Pending JP2022028659A (ja) | 2013-06-26 | 2021-10-14 | 新規抗体フレームワーク |
| JP2023199881A Pending JP2024026176A (ja) | 2013-06-26 | 2023-11-27 | 新規抗体フレームワーク |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522319A Active JP6708544B2 (ja) | 2013-06-26 | 2014-06-26 | 新規抗体フレームワーク |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021169020A Pending JP2022028659A (ja) | 2013-06-26 | 2021-10-14 | 新規抗体フレームワーク |
| JP2023199881A Pending JP2024026176A (ja) | 2013-06-26 | 2023-11-27 | 新規抗体フレームワーク |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10174102B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3013864A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6708544B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR20240000622A (cg-RX-API-DMAC7.html) |
| CN (2) | CN113943366B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2014301629B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2914829A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1218549A1 (cg-RX-API-DMAC7.html) |
| IL (3) | IL313351A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ714320A (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201811017QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014206561A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313351A (en) | 2013-06-26 | 2024-08-01 | Numab Therapeutics AG | New frameworks for antibodies |
| MX395604B (es) | 2015-06-15 | 2025-03-25 | Numab Therapeutics AG | Formato de anticuerpo multiespecífico heterodimérico. |
| EP3420000A1 (en) | 2016-02-25 | 2019-01-02 | Cell Medica Switzerland AG | Modified cells for immunotherapy |
| KR102449711B1 (ko) | 2016-03-17 | 2022-09-30 | 누맙 이노베이션 아게 | 항-TNFα-항체 및 이의 기능성 단편 |
| ES2843974T3 (es) | 2016-03-17 | 2021-07-21 | Tillotts Pharma Ag | Anticuerpos anti-TNF alfa y fragmentos funcionales de los mismos |
| AU2017235465B2 (en) | 2016-03-17 | 2024-03-28 | Numab Therapeutics AG | Anti-TNFα-antibodies and functional fragments thereof |
| KR102392746B1 (ko) | 2016-03-17 | 2022-04-29 | 누맙 이노베이션 아게 | 항-TNFα-항체 및 이의 기능성 단편 |
| EP3219726B1 (en) | 2016-03-17 | 2020-12-02 | Tillotts Pharma AG | Anti-tnf alpha-antibodies and functional fragments thereof |
| GB201621591D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Antibody molecules and method |
| WO2018224441A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| KR102771043B1 (ko) | 2017-06-05 | 2025-02-26 | 누맙 세러퓨틱스 아게 | 적어도 cd3 및 hsa를 표적화하는 헤테로-이량체 다중 특이적 항체 포맷 |
| ES3015105T3 (en) | 2017-06-05 | 2025-04-29 | Numab Therapeutics AG | Anti-cd3 epsilon antibodies |
| WO2018224439A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| JP7130678B2 (ja) * | 2017-06-05 | 2022-09-05 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗ｈｓａ抗体 |
| US20200157224A1 (en) * | 2017-06-25 | 2020-05-21 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| CN116199785A (zh) | 2017-06-25 | 2023-06-02 | 西雅图免疫公司 | 多特异性抗体及其制备和使用方法 |
| EP3459968A1 (en) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
| US12503505B2 (en) | 2019-01-31 | 2025-12-23 | Numab Therapeutics AG | Multispecific antibodies having specificity for TNFα and IL-17A, antibodies targeting IL-17A, and methods of use thereof |
| EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| AU2021413899A1 (en) * | 2020-12-30 | 2023-08-03 | Ascendo Biotechnology, Inc. | Monoclonal antibody against human mac-1 and uses thereof |
| CA3208905A1 (en) | 2021-02-12 | 2022-08-18 | Boehringer Ingelheim International Gmbh | Complement c3 antigen binding proteins |
| WO2022192625A1 (en) | 2021-03-11 | 2022-09-15 | IgGenix, Inc. | Methods and systems for predicting allergic response |
| AU2022420788A1 (en) | 2021-12-22 | 2024-05-16 | Boehringer Ingelheim International Gmbh | Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases |
| WO2024098026A2 (en) * | 2022-11-04 | 2024-05-10 | Mink Therapeutics, Inc. | B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| WO2005016950A1 (en) | 2003-08-07 | 2005-02-24 | Epitomics, Inc. | Methods for humanizing rabbit monoclonal antibodies |
| WO2008004834A1 (en) | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
| FR2910896B1 (fr) * | 2006-12-29 | 2012-11-16 | Lab Francais Du Fractionnement | Anticorps monoclonal dirige contre le recepteur humain des ldl |
| TWI501976B (zh) | 2007-05-21 | 2015-10-01 | Alder Biopharmaceuticals Inc | 抗ＴＮＦ－α之抗體及其用途 |
| KR101573086B1 (ko) | 2007-06-25 | 2015-11-30 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 항체를 변형시키는 방법, 및 기능적 특성이 개선된 변형된 항체 |
| AU2009264564B2 (en) | 2008-06-25 | 2014-05-08 | Novartis Ag | Stable and soluble antibodies inhibiting TNFalpha |
| LT3216803T (lt) * | 2008-06-25 | 2020-06-10 | Novartis Ag | Stabilūs ir tirpūs antikūnai, slopinantys vegf |
| SI2752428T1 (sl) * | 2008-06-25 | 2020-03-31 | Novartis Ag | Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa |
| WO2010144780A1 (en) | 2009-06-12 | 2010-12-16 | University Of Kansas | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state |
| EA201291133A1 (ru) * | 2010-04-30 | 2013-04-30 | Алексион Фармасьютикалз, Инк. | Антитела, обладающие пониженной иммуногенностью в организме человека |
| WO2012163519A1 (en) * | 2011-05-27 | 2012-12-06 | Dutalys | Antibodies with improved folding stability |
| IL313351A (en) | 2013-06-26 | 2024-08-01 | Numab Therapeutics AG | New frameworks for antibodies |
| EP3459968A1 (en) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
-
2014
- 2014-06-26 IL IL313351A patent/IL313351A/en unknown
- 2014-06-26 US US14/900,550 patent/US10174102B2/en active Active
- 2014-06-26 KR KR1020237043185A patent/KR20240000622A/ko active Pending
- 2014-06-26 IL IL243311A patent/IL243311B/en unknown
- 2014-06-26 WO PCT/EP2014/001730 patent/WO2014206561A1/en not_active Ceased
- 2014-06-26 KR KR1020167001339A patent/KR102286053B1/ko active Active
- 2014-06-26 IL IL293477A patent/IL293477B2/en unknown
- 2014-06-26 CN CN202111136784.7A patent/CN113943366B/zh active Active
- 2014-06-26 KR KR1020227006072A patent/KR20220029763A/ko not_active Ceased
- 2014-06-26 NZ NZ714320A patent/NZ714320A/en unknown
- 2014-06-26 JP JP2016522319A patent/JP6708544B2/ja active Active
- 2014-06-26 AU AU2014301629A patent/AU2014301629B2/en active Active
- 2014-06-26 KR KR1020217024096A patent/KR20210097829A/ko not_active Ceased
- 2014-06-26 HK HK16106054.2A patent/HK1218549A1/zh unknown
- 2014-06-26 SG SG10201811017QA patent/SG10201811017QA/en unknown
- 2014-06-26 SG SG11201509899PA patent/SG11201509899PA/en unknown
- 2014-06-26 EP EP14737144.7A patent/EP3013864A1/en active Pending
- 2014-06-26 CN CN201480036689.1A patent/CN105579472B/zh active Active
- 2014-06-26 CA CA2914829A patent/CA2914829A1/en active Pending
-
2018
- 2018-10-10 US US16/156,036 patent/US11427628B2/en active Active
-
2019
- 2019-06-17 JP JP2019111990A patent/JP2019201643A/ja not_active Withdrawn
-
2020
- 2020-04-27 AU AU2020202770A patent/AU2020202770B2/en active Active
-
2021
- 2021-10-14 JP JP2021169020A patent/JP2022028659A/ja active Pending
-
2022
- 2022-08-29 US US17/822,959 patent/US20230212265A1/en active Pending
-
2023
- 2023-11-27 JP JP2023199881A patent/JP2024026176A/ja active Pending